Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership
    RAS Technology dives deeper into European wagering with Playbook Engineering partnership
    • News

  • BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers
    BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers
    • News

  • Markets continue to push higher as Powell signals peak rates
    Markets continue to push higher as Powell signals peak rates
    • Market Update

  • Amid debt dispute, Electro Optic Systems reports revenue guidance of $210 to $230 million
    Amid debt dispute, Electro Optic Systems reports revenue guidance of $210 to $230 million
    • News

  • Use your mobile to check for arrhythmia as Advanced Health Intelligence launches AF-Scan
    Use your mobile to check for arrhythmia as Advanced Health Intelligence launches AF-Scan
    • News

  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday
    The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday
    • News

  • US markets see late drive higher, XJO to open flat
    US markets see late drive higher, XJO to open flat
    • Market Update

  • Little Green Pharma has big news: a new CEO and 37% revenue growth
    Little Green Pharma has big news: a new CEO and 37% revenue growth
    • News

  • The BESS-T bet: GenusPlus and Samsung joint venture awarded $200m to build energy solution
    The BESS-T bet: GenusPlus and Samsung joint venture awarded $200m to build energy solution
    • News

Osteopore partners with Terumo for collaboration on regenerative bone marrow

  • In News
  • February 1, 2021
  • Alfred Chan
Osteopore partners with Terumo for collaboration on regenerative bone marrow

Medtech company Osteopore (ASX: OSX) will soon have it’s 3D-printed bone regeneration products in the view of major international medical markets through a new collaboration with one of the world’s largest medical companies.

The cross-promotion agreement is with Terumo Blood and Cell Technologies which is wholly owned by Japanese medical conglomerate Terumo (TYO: 4543) which generates more than $8 billion annual revenue.

Between the two parties, respective sales teams will be educated in each others products where Terumo Blood and Cell Technologies’ Autologous Biologics (TAB) technology extracts concentrated bone marrow for bone regeneration while Osteopore’s provides biomimetic scaffolding to guide the bone tissue formation.

Targeted applications of the cross-promoted products include Neurosurgery, Orthopaedics and Reconstructive surgeries and will draw upon Terumo’s extensive network of blood centres, hospitals, therapeutic clinics, researchers, and private medical practices in the Asia-Pacific region.

Further commercial opportunities will be explored by the partnership which would commence with investigator-initiated studies.

For the 12 months ending 31 December 2020, Osteopore reported $1.5 million in sales which represented a 36% increase from the previous year. This was generated primarily through Osteopore’s 3D-printed scaffold tissue that naturally dissolves over time to leave only natural, healthy bone tissue, significantly reducing post-surgery complications commonly associated with permanent bone implants.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023
  •  
  •  
  •  
  •  
  • autologous biologics
  • medtech
  • orthopaedics
  • Osteopore
  • OSX
  • reconstructive surgery
  • terumo
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.